HomeCompareVRSRF vs ABBV

VRSRF vs ABBV: Dividend Comparison 2026

VRSRF yields 20000000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VRSRF wins by $4.875981653489057e+49M in total portfolio value
10 years
VRSRF
VRSRF
● Live price
20000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875981653489057e+49M
Annual income
$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full VRSRF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — VRSRF vs ABBV

📍 VRSRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVRSRFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VRSRF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VRSRF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VRSRF
Annual income on $10K today (after 15% tax)
$1,700,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, VRSRF beats the other by $41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VRSRF + ABBV for your $10,000?

VRSRF: 50%ABBV: 50%
100% ABBV50/50100% VRSRF
Portfolio after 10yr
$2.4379908267445285e+49M
Annual income
$24,379,668,474,955,630,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

VRSRF
No analyst data
Altman Z
-17.1
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VRSRF buys
0
ABBV buys
0
No recent congressional trades found for VRSRF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVRSRFABBV
Forward yield20000000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.875981653489057e+49M$102.3K
Annual income after 10y$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$4.875978515990276e+49M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VRSRF vs ABBV ($10,000, DRIP)

YearVRSRF PortfolioVRSRF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$2,000,010,700$2,000,000,000.00$11,550$430.00+$2000.00MVRSRF
2$373,835,915,712,384$373,833,775,700,934.50$13,472$627.96+$373835915.70MVRSRF
3$65,304,953,364,964,970,000$65,304,553,360,535,160,000.00$15,906$926.08+$65304953364964.95MVRSRF
4$10,661,728,832,755,500,000,000,000$10,661,658,956,455,399,000,000,000.00$19,071$1,382.55+$10661728832755499008.00MVRSRF
5$1,626,767,783,781,495,000,000,000,000,000$1,626,756,375,731,643,800,000,000,000,000.00$23,302$2,095.81+$1.626767783781495e+24MVRSRF
6$231,974,330,054,625,100,000,000,000,000,000,000$231,972,589,413,096,470,000,000,000,000,000,000.00$29,150$3,237.93+$2.319743300546251e+29MVRSRF
7$30,915,106,403,922,057,000,000,000,000,000,000,000,000$30,914,858,191,388,900,000,000,000,000,000,000,000,000.00$37,536$5,121.41+$3.0915106403922057e+34MVRSRF
8$3,850,507,985,839,278,000,000,000,000,000,000,000,000,000,000$3,850,474,906,675,425,000,000,000,000,000,000,000,000,000,000.00$50,079$8,338.38+$3.8505079858392777e+39MVRSRF
9$448,210,261,035,314,200,000,000,000,000,000,000,000,000,000,000,000$448,206,140,991,769,400,000,000,000,000,000,000,000,000,000,000,000.00$69,753$14,065.80+$4.4821026103531426e+44MVRSRF
10$48,759,816,534,890,570,000,000,000,000,000,000,000,000,000,000,000,000,000$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00$102,337$24,771.77+$4.875981653489057e+49MVRSRF

VRSRF vs ABBV: Complete Analysis 2026

VRSRFStock

Versarien plc, an engineering materials company, provides engineering solutions for various industry sectors in the United Kingdom, rest of Europe, North America, and internationally. The company operates in two segments, Graphene and Plastic Products, and Hard Wear and Metallic Products. The Graphene and Plastic Products segment offers graphene products, such as Nanene, a few-layer graphene; Polygrene, a graphene enhanced polymer; Hexotene, a few-layer hexagonal boron nitride nano-platelet powder; and graphene-based nanomaterials for energy storage devices, as well as a range of electrically conductive graphene inks for various printing processes, substrates, and applications under the Graphinks name. This segment also provides graphene enhanced plastic products, including graphene enhanced mobile accessories, injection molding products, tool boxes, transit trays, PU foam tanks, and vacuum forming products. The Hard Wear and Metallic Products segment also offers sintered tungsten carbide products comprising special inserts and blanks, cutting knives, wear-resistant parts, nozzles and valve inserts for flow control, and defense and aerospace tungsten carbide parts for use in arduous environmental applications; and micro-porous metals for the thermal management industry, as well as supplies extruded aluminum products, such as aluminum industrial products and aluminum heat sinks. It also manufactures, sells, and supplies anti-bacterial and antiviral masks; and hospital bed panels and visors. The company was founded in 2010 and is based in Cheltenham, the United Kingdom.

Full VRSRF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this VRSRF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VRSRF vs SCHDVRSRF vs JEPIVRSRF vs OVRSRF vs KOVRSRF vs MAINVRSRF vs JNJVRSRF vs MRKVRSRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.